Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)

被引：0
|
作者：
Quintyne, K. I. [1 ]
Woulfe, B. [2 ]
Dee, A. [3 ]
Gupta, R. [2 ]
机构：
[1] NCCP, Community Oncol, Dublin, Ireland
[2] Midwestern Reg Hosp, Med Oncol, Limerick, Ireland
[3] HSE Midwest, Publ Hlth, Limerick, Ireland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1031P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [2] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [3] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [4] COST-EFFECTIVENESS ANA LYSIS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A735 - A735
  • [5] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [6] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [7] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [8] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    [J]. BMC Health Services Research, 19
  • [9] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [10] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
12345